Rodino-Klapac Louise 4
4 · Sarepta Therapeutics, Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Rodino-Klapac Louise
President, R&D and Tech Ops
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-01+8,125→ 232,155 total - Tax Payment
Common Stock
[F2]2026-03-02$16.20/sh−3,718$60,232→ 228,437 total - Tax Payment
Common Stock
[F3]2026-03-02$16.20/sh−767$12,425→ 227,670 total - Exercise/Conversion
Performance Stock Units
[F1]2026-03-01−8,125→ 0 total→ Common Stock (8,125 underlying)
Footnotes (3)
- [F1]Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.
- [F2]Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of a PSU award granted on March 1, 2024.
- [F3]Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.
Signature
/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Louise Rodino-Klapac|2026-03-03